Evidence map›Paper›PMID 42185795›Full record

ArticleBMC cancer2026

The landscape of MET alterations in non-small cell lung cancer in Southeastern China: a real-world study.

Sisi Zheng, Ziyi Zuo, Rixu Lin, Xiaoxiao Zhang, Lujie Huang, Mengsi Cai, Yifan Ye, Dan Yao, Xiaoying Huang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sisi Zheng *Pulmonary Division, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou Key Laboratory of Interdisciplinary and Translational Medicine, Wenzhou Key Laboratory of Heart and Lung, Wenzhou, Zhejiang, 325035, China.
Ziyi Zuo *Pulmonary Division, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou Key Laboratory of Interdisciplinary and Translational Medicine, Wenzhou Key Laboratory of Heart and Lung, Wenzhou, Zhejiang, 325035, China.
Rixu Lin *Pathology Department, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China.
Xiaoxiao ZhangPulmonary Division, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou Key Laboratory of Interdisciplinary and Translational Medicine, Wenzhou Key Laboratory of Heart and Lung, Wenzhou, Zhejiang, 325035, China.
Lujie HuangPulmonary Division, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou Key Laboratory of Interdisciplinary and Translational Medicine, Wenzhou Key Laboratory of Heart and Lung, Wenzhou, Zhejiang, 325035, China.
Mengsi CaiPulmonary Division, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou Key Laboratory of Interdisciplinary and Translational Medicine, Wenzhou Key Laboratory of Heart and Lung, Wenzhou, Zhejiang, 325035, China.
Yifan YePulmonary Division, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou Key Laboratory of Interdisciplinary and Translational Medicine, Wenzhou Key Laboratory of Heart and Lung, Wenzhou, Zhejiang, 325035, China.
Dan YaoPulmonary Division, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou Key Laboratory of Interdisciplinary and Translational Medicine, Wenzhou Key Laboratory of Heart and Lung, Wenzhou, Zhejiang, 325035, China. yaodan@wzhospital.cn.
Xiaoying HuangPulmonary Division, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou Key Laboratory of Interdisciplinary and Translational Medicine, Wenzhou Key Laboratory of Heart and Lung, Wenzhou, Zhejiang, 325035, China. huangxiaoying@wzhospital.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMET is a key driver in NSCLC yet comprehensive, multi-subtype real-world data in China are lacking.

methodsReal-world data were collected from MET-altered NSCLC patients diagnosed at a comprehensive hospital in southeastern China (July 2021-December 2023). Four subgroups were analyzed: MET IHC-Positive, MET Amplification, MET Exon 14 skipping, and MET Other Mutations. Demographics, risk factors, comorbidities, pathology, co-mutation, and treatment patterns were compared. With 2-year follow-up, survival outcomes and MET-TKI benefit were analyzed.

resultsAmong 574 patients: MET IHC-Pos (81.4%), MET-Amp (11.0%), MET-Ex14 (4.70%), and Others (2.96%). Patients were predominantly elderly, male, with > 40% smoking history and > 35% hypertension. Pathological specimens were mainly obtained via bronchoscopy or percutaneous lung puncture. Adenocarcinoma dominated all subtypes (> 70%), increasing with IHC intensity in MET IHC-Pos (p < 0.05). MET-Amp showed the highest advanced stage (87.3%), bone (36.5%) and brain metastasis (17.5%). TP53 was the most common co-mutation (20.7%-25.0%). Targeted therapy predominated (Line 1st: 54.6%, Line 2nd: 38.9%), followed by chemotherapy plus immunotherapy. The 24-month OS was lower in MET-Amp (44.4%) and MET-Ex14 (48.1%) than in MET IHC-Pos (57.2%) and Others (58.8%). The 24-month OS (MET-TKI treated vs. untreated) was: 69.2% vs. 38.5% (MET IHC-Pos 2 + /3 +), 71.4% vs. 25.0% (MET-Ex14), and 47.4% vs. 42.9% (MET-Amp).

conclusionsMET alterations occur predominantly in the elderly, males, and smokers. MET-Ex14 shows driver-dependent characteristics with clear MET-TKI benefit. MET-Amp presents the most aggressive phenotype. MET IHC-Pos predominates (> 80%) with heterogeneity; the 2 + /3 + may benefit from MET-TKI. These findings inform subtype-based management of MET-altered NSCLC in southeastern China.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsProto-Oncogene Proteins c-metAdultAgedChinaFemaleHumansMaleMiddle AgedMutationMET protein, humanProto-Oncogene Proteins c-metMETMET-TKINSCLCReal-worldSurvival analysis

Identifiers

PMID42185795
PMCPMC13393253

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.